Overcoming Alcohol Addiction in Patients with Alcohol-Related Liver Disease

  • Gene Y. ImEmail author
Management of Cirrhotic Patient (A Cardenas and P Tandon, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Management of the Cirrhotic Patient


Purpose of Review

This review provides a brief overview of key concepts in addiction medicine and provides tips and tricks as it pertains to treating patients with alcohol addiction in the setting of advanced alcohol-related liver disease (ALD).

Recent Findings

Understanding the brain disease model of addiction by both providers and patients is a vital springboard for establishing a therapeutic relationship. Despite a paucity of high-quality evidence, psychosocial treatments have withstood the test of time and still form the foundation of alcohol use disorder (AUD) treatment in advanced ALD. Despite the inescapable link between AUD) and advanced ALD, there are no FDA-approved medications for use in this special population. In this urgent subgroup, only baclofen, used off-label, has been shown to be effective for AUD in randomized controlled trials.


An integrated, multidisciplinary and longitudinal approach remains the best option for the management of AUD in advanced ALD.


Alcohol-use disorder Alcohol-related liver disease Baclofen Alcoholism Craving Alcohol-related cirrhosis 


Compliance with Ethical Standards

Conflicts of Interest

Gene Im declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: Author; 2013.Google Scholar
  2. 2.
    • Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016;65:618–30 Important review describing state of the art dilemmas and nuances in treating this population. CrossRefGoogle Scholar
  3. 3.
    •• Vaillant GE. A 60-year follow-up of alcoholic men. Addiction. 2003;98(8):1043–51 Seminal longitudinal study of AUD, describing its natural history in men. CrossRefGoogle Scholar
  4. 4.
    Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–45.CrossRefGoogle Scholar
  5. 5.
    World Health Organization. Global status report on alcohol and health 2018. Available from: Accessed October 28, 2018.
  6. 6.
    • Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72:757–66 Important recent U.S. epidemiological survey of increasing AUD prevalence. CrossRefGoogle Scholar
  7. 7.
    Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68(3):872–82.CrossRefGoogle Scholar
  8. 8.
    Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ. 2018;362:k2817.CrossRefGoogle Scholar
  9. 9.
    GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015–35.CrossRefGoogle Scholar
  10. 10.
    Wood E, Samet JH, Volkow ND. Physician education in addiction medicine. JAMA. 2013;310(16):1673–4.CrossRefGoogle Scholar
  11. 11.
    • Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363–71 Important review of the brain disease model of addiction suited for the clinician. CrossRefGoogle Scholar
  12. 12.
    Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, et al. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry. 2008;9(1):6–23.CrossRefGoogle Scholar
  13. 13.
    Palmer RH, McGeary JE, Heath AC, Keller MC, Brick LA, Knopik VS. Shared additive genetic influences on DSM-IV criteria for alcohol dependence in subjects of European ancestry. Addiction. 2015;110(12):1922–31.CrossRefGoogle Scholar
  14. 14.
    Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc. 2004;63:49–63.CrossRefGoogle Scholar
  15. 15.
    •• Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet. 2015;47(12):1443–8 Large seminal study confirming old and identifying new genetic risk factors for developing alcohol-related cirrhosis compared to heavy drinkers without cirrhosis. CrossRefGoogle Scholar
  16. 16.
    Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378(12):1096–106.CrossRefGoogle Scholar
  17. 17.
    Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl. 2011 Jul;17(7):751–9.CrossRefGoogle Scholar
  18. 18.
    • Babor TF. The classification of alcoholics: typology theories from the 19th century to the present. Alcohol Health Res World. 1996;20(1):6–14 Good expert review of AUD typologies and their utility. Google Scholar
  19. 19.
    Longabaugh R, Wirtz PW, Zweben A, Stout RL. Network support for drinking, alcoholics anonymous and long-term matching effects. Addiction. 1998 Sep;93(9):1313–33.CrossRefGoogle Scholar
  20. 20.
    Miller WR, Rollnick S. Motivational Interviewing, Third Edition. Guilford Press; 2012.Google Scholar
  21. 21.
    Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.CrossRefGoogle Scholar
  22. 22.
    Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rabin L, et al. Prognostic factors in alcoholic liver disease. Am J Gastroenterol. 1991;86(2):210–6.Google Scholar
  23. 23.
    Parés A, Caballería J, Bruguera M, Torres M, Rodés J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol. 1986;2(1):33–42.CrossRefGoogle Scholar
  24. 24.
    Vaillant GE, Hiller-Sturmhöfel S. The natural history of alcoholism. Alcohol Health Res World. 1996;20(3):152–61.Google Scholar
  25. 25.
    • Weinrieb RM, Van Horn DH, McLellan AT, Volpicelli JR, Calarco JS, Lucey MR. Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates. J Addict Dis. 2001;20(2):105–19 Important study of AUD patients with ALD requiring LT, highlighting their differences (and therapeutic challenges) from other AUD patients. CrossRefGoogle Scholar
  26. 26.
    Weinrieb RM, Van Horn DH, McLellan AT, Volpicelli JR, Calarco JS, Lucey MR. Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates. J Addict Dis. 2001;20(2):105–19.Google Scholar
  27. 27.
    Miller WR, Benefield RG, Tonigan JS. Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles. J Consult Clin Psychol. 1993;61(3):455–61.CrossRefGoogle Scholar
  28. 28.
    Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017;130(2):124–34.CrossRefGoogle Scholar
  29. 29.
    Gustafson DH, McTavish FM, Chih MY, Atwood AK, Johnson RA, Boyle MG, et al. A smartphone application to support recovery from alcoholism: a randomized clinical trial. JAMA Psychiatry. 2014;71(5):566–72.CrossRefGoogle Scholar
  30. 30.
    Carroll KM, Connors GJ, Cooney NL, DiClemente CC, Donovan DM, Kadden RR, et al. Internal validity of project MATCH treatments: discriminability and integrity. J Consult Clin Psychol. 1998;66(2):290–303.CrossRefGoogle Scholar
  31. 31.
    Copello A, Orfor J, Hodgson R, Tober G, Barrett C, UKATT Research Team. United Kingdom Alcohol Treatment Trial. Social behaviour and network therapy basic principles and early experiences. Addict Behav. 2002;27(3):345–66.CrossRefGoogle Scholar
  32. 32.
    Klimas J, Tobin H, Field C-A, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Drugs and Alcohol Group, ed. Cochrane Database Syst Rev. 2014;95:CD009269.Google Scholar
  33. 33.
    •• Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–22 Seminal study of the only RCT trial of AUD pharmacotherapy in patients with ALD cirrhosis. CrossRefGoogle Scholar
  34. 34.
    Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70–7.CrossRefGoogle Scholar
  35. 35.
    Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group et al. Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety. Alcohol Clin Exp Res. 2019;43(1):158–69.Google Scholar
  36. 36.
    Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7(4):277–86.CrossRefGoogle Scholar
  37. 37.
    • Lyon J. More Treatments on deck for alcohol use disorder. JAMA. 2017;317(22):2267–9 A nice short review highlighting the pipeline of pharmacotherapies for AUD. CrossRefGoogle Scholar
  38. 38.
    Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–900.CrossRefGoogle Scholar
  39. 39. Accessed December 20, 2018.
  40. 40.
    Ragia G, Manolopoulos VG. Personalized medicine of alcohol addiction: pharmacogenomics and beyond. Curr Pharm Biotechnol. 2017;18(3):221–30.CrossRefGoogle Scholar
  41. 41.
    Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009;14(3):328–37.CrossRefGoogle Scholar
  42. 42.
    •• Khan A, Tansel A, White DL, Kayani WT, Bano S, Lindsay J, et al. Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. Clin Gastroenterol Hepatol. 2016;14(2):191–202 Important systematic review of psychosocial therapies for AUD specifically in patients with established liver disease. CrossRefGoogle Scholar
  43. 43.
    Peters TJ, Kotowicz J, Nyka W, Kozubski W, Kuznetsov V, Vanderbist F, et al. Treatment of alcoholic polyneuropathy with vitamin B complex: a randomised controlled trial. Alcohol Alcohol. 2006;41(6):636–42.CrossRefGoogle Scholar
  44. 44.
    Jarvis M, Williams J, Hurford M, Lindsay D, Lincoln P, Giles L, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017;11(3):163–73.CrossRefGoogle Scholar
  45. 45.
    • Staufer K, Yegles M. Biomarkers for detection of alcohol consumption in liver transplantation. World J Gastroenterol. 2016;22(14):3725–34 Good review of clinically relevant alcohol biomarkers from a expert in the field. CrossRefGoogle Scholar
  46. 46.
    Cabezas J, Lucey MR, Bataller R. Biomarkers for monitoring alcohol use. Clin Liver Dis. 2016;8(3):59–63.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Icahn School of Medicine at Mount Sinai, Division of Liver DiseasesRecanati-Miller Transplantation InstituteNew YorkUSA

Personalised recommendations